Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “SHR-A1811”

63 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 63 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT06666166
What this trial is testing

SHR-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer

Who this might be right for
Advanced Gastric CarcinomaAdvanced Gastroesophageal Junction AdenocarcinomaAdvanced Colorectal Cancer
Yunpeng Liu 28
Large-scale testing (Phase 3)Looking for participantsNCT07196774
What this trial is testing

A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer

Who this might be right for
Early-stage or Locally Advanced HER2-positive Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 740
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07307287
What this trial is testing

SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study

Who this might be right for
SHR-A1811HER2-Postive Breast CancerHR+ Breast Cancer+2 more
Tianjin Medical University Cancer Institute and Hospital 30
Not applicableNot Yet RecruitingNCT07377916
What this trial is testing

Clinical Study of SHR-A1811 Combined With Pertuzumab as Second-Line Therapy in Patients With HER2-Altered Advanced NSCLC

Who this might be right for
Non-Small Cell Lung Cancer
The First Affiliated Hospital of Guangzhou Medical University 60
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07466303
What this trial is testing

Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer

Who this might be right for
Breast CancerSerplulimab Combined With SHR-A1811 as Neoadjuvant Therapy for Triple-Negative Breast Cancer
Xijing Hospital 84
Testing effectiveness (Phase 2)Looking for participantsNCT06859775
What this trial is testing

SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer

Who this might be right for
Recurrent or Metastatic Cervical Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 100
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06973525
What this trial is testing

This Study Aims to Optimize Neoadjuvant Therapy for HER2-positive Breast Cancer by Implementing a Dynamic Monitoring-guided Treatment Strategy.

Who this might be right for
HER2-positive Breast Cancer
Hebei Medical University Fourth Hospital 30
Large-scale testing (Phase 3)Active Not RecruitingNCT05424835
What this trial is testing

A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane

Who this might be right for
HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
Jiangsu HengRui Medicine Co., Ltd. 381
Testing effectiveness (Phase 2)Looking for participantsNCT06927180
What this trial is testing

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Who this might be right for
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Henan Cancer Hospital 180
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07281209
What this trial is testing

SHR-A1811 Combined With Adebelimumab as Neoadjuvant Therapy for Resectable HER2-Altered Non-Small Cell Lung Cancer

Who this might be right for
NSCLC
Shanghai Chest Hospital 40
Large-scale testing (Phase 3)Not Yet RecruitingNCT07382687
What this trial is testing

Famitinib Combined With SHR-A1811, Versus SHR-A1811 for CDK4/6 Inhibitors-resistent Advanced HR+/HER2- Breast Cancer With SNF4 Subtype

Who this might be right for
Breast Cancer
Fudan University 248
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06975475
What this trial is testing

SHR-A1811 and THPy in First or Second Line for HER2 Positive Advanced Breast Cancer Brain Metastases

Who this might be right for
Breast Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 60
Testing effectiveness (Phase 2)Looking for participantsNCT05896020
What this trial is testing

SHR-A1811 in Subjects With Gynaecologic Oncology

Who this might be right for
Gynaecological Malignancies
Jiangsu HengRui Medicine Co., Ltd. 225
Early research (Phase 1)Looking for participantsNCT06710990
What this trial is testing

Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 32
Testing effectiveness (Phase 2)Looking for participantsNCT06778031
What this trial is testing

A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer

Who this might be right for
HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 54
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06361979
What this trial is testing

SHR-A1811 Combined With Bevacizumab in HER2-positive Breast Cancer With Brain Metastases

Who this might be right for
Breasr Cancer
Huihua Xiong 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07528898
What this trial is testing

Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study.

Who this might be right for
Breast Cancer
Hebei Medical University Fourth Hospital 100
Large-scale testing (Phase 3)Looking for participantsNCT06126640
What this trial is testing

A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy

Who this might be right for
HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
Jiangsu HengRui Medicine Co., Ltd. 1,600
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07132242
What this trial is testing

SHR-A1811 Combine With Pyrotinib for Locally Advanced/Metastatic HER2 Positive Breast Cancer

Who this might be right for
Metastatic Breast Cancer With HER2 Positive
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 84
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07177950
What this trial is testing

A Two-cohort Study of SHR-A1811 in the Treatment of HER2-positive Breast Cancer With Brain Metastases

Who this might be right for
Breast CancerBrain MetastasesLeptomeningeal Metastasis
Peking University Cancer Hospital & Institute 51
Load More Results